Phosphorylcholine monoclonal antibody - Athera Biotechnologies

Drug Profile

Phosphorylcholine monoclonal antibody - Athera Biotechnologies

Alternative Names: 3G10; Fully human monoclonal IgG phosphorylcholine antibody - Athera Biotechnologies; IgG phosphorylcholine antibody; PC-mAb; PCmab; Phosphorylcholine monoclonal antibody - Athera

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dyax
  • Developer Athera Biotechnologies
  • Class Cardiovascular therapies; Monoclonal antibodies
  • Mechanism of Action LDL receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal failure
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Atherosclerosis
  • Phase I Cardiovascular disorders
  • Clinical Phase Unknown Peripheral arterial disorders
  • Preclinical Coronary artery restenosis

Most Recent Events

  • 06 Sep 2017 Phase-II clinical trials in Atherosclerosis in Sweden, Netherlands (IV) (EudraCT2017-002106-13)
  • 30 Aug 2017 Athera Biotechnologies plans a phase IIa study of phosphorylcholine monoclonal antibody for Peripheral arterial disorders in 2017
  • 28 Aug 2017 Phosphorylcholine monoclonal antibody - Athera Biotechnologies receives Orphan Drug status for Renal failure (End stage renal disease) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top